Related references
Note: Only part of the references are listed.Outcome of Transplantation for Myelofibrosis
Karen K. Ballen et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis
Kebede Hussein et al.
BLOOD (2010)
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
Francesco Passamonti et al.
BLOOD (2010)
Validation of cytogenetic-based risk stratification in primary myelofibrosis
Elisa Rumi et al.
BLOOD (2010)
Allogeneic hematopoietic cell transplantation versus drugs in myelofibrosis: the risk-benefit balancing act
A. Tefferi
BONE MARROW TRANSPLANTATION (2010)
JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival
A. Tefferi et al.
LEUKEMIA (2010)
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis
A. Tefferi et al.
LEUKEMIA (2010)
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
Francisco Cervantes et al.
BLOOD (2009)
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele
Paola Guglielmelli et al.
BLOOD (2009)
The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course
Constantine S. Tam et al.
BLOOD (2009)
The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan
Tomonori Hidaka et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2009)
Dynamic Model for Predicting Death Within 12 Months in Patients With Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
Constantine S. Tam et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients
A. Pardanani et al.
LEUKEMIA (2009)
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis
A. Tefferi et al.
LEUKEMIA (2009)
Risk factors for leukemic transformation in patients with primary myelofibrosis
Jocelin Huang et al.
CANCER (2008)
Choosing between stem cell therapy and drugs in myelofibrosis
N. Kroeger et al.
LEUKEMIA (2008)
TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients
T. L. Lasho et al.
LEUKEMIA (2008)
Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival
A. Tefferi et al.
LEUKEMIA (2008)
Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders
F. Cervantes et al.
LEUKEMIA (2008)
Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms:: a critical reappraisal
A. M. Vannucchi et al.
LEUKEMIA (2008)
JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials
A. Pardanani
LEUKEMIA (2008)
Myelodysplastic syndrome with isolated deletion of chromosome 20q: an indolent disease with minimal morphological dysplasia and frequent thrombocytopenic presentation
Raavi Gupta et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Validation and comparison of contemporary prognostic models in primary myelofibrosis - Analysis based on 334 patients from a single institution
Ayalew Tefferi et al.
CANCER (2007)
Chromosome 7 deletions are associated with unfavorable prognosis in myelofibrosis with myeloid metaplasia
K Strasser-Weippl et al.
BLOOD (2005)
Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia
A Tefferi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Share Paper
